⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
STOK News
Stoke Therapeutics, Inc. Common Stock
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16 th European Epilepsy Congress (EEC)
businesswire.com
STOK
BIIB
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
globenewswire.com
STOK
BIIB
Dravet Syndrome Market Trends Indicate Sustained Growth During the Forecast Period (2026–2036), Driven by Novel Treatment Approaches | DelveInsight
globenewswire.com
BIIB
HRMY
XNCR
AZN
LLY
PFE
REGN
NVS
TSLA
TAK
GSK
JNJ
UCB
BHF
PRAX
XENE
AQST
TNDM
INCY
MRK
ABBV
BMY
AMGN
GILD
VRTX
CRSP
EDIT
NTLA
SRPT
ALNY
EXAS
TEVA
AXSM
CYTK
INSM
KODK
LPCN
MNKD
NBIX
NCLH
ONCY
ORIC
PBYI
PEGA
PLRX
PRGS
QGEN
RGNX
ROST
RYAAY
SNOW
SWKS
SYK
TGT
TRMB
TXG
ULTA
VRSK
WDC
WVE
XOM
ZBRA
ZNTL
ZTS
STOK
IONS
MOMO
BBAR
CTXR
MBIO
GNS
NEON
OVID
BHVN
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
businesswire.com
STOK
Form 8-K
sec.gov
STOK
Form 8-K
sec.gov
STOK
BIIB
Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates
businesswire.com
STOK
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates
businesswire.com
STOK
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
businesswire.com
STOK
Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer
businesswire.com
STOK
BIIB